FDA approves non-alcoholic Docetaxel Injection

[News]

Teikoku Pharma USA, Inc. announced today that the U.S. Food and Drug Administration has approved Docetaxel Injection, Non-Alcohol Formula ("Docetaxel Injection") for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

More... (http://www.news-medical.net/news/20151229/FDA-approves-non-alcoholic-Docetaxel-Injection.aspx)